Aprea Therapeutics Valuation
| APRE Stock | USD 0.73 0.02 3.11% |
Aprea Therapeutics is undervalued. Aprea Therapeutics shows a prevailing Real Value of $2.21 per share. The current price of the firm is $0.7267. Our model approximates the value of Aprea Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.75, current valuation of (9.59 M), and Shares Owned By Insiders of 19.54 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Aprea Therapeutics' valuation include:
Undervalued
Today
Please note that Aprea Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Aprea Therapeutics is based on 3 months time horizon. Increasing Aprea Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Aprea stock is determined by what a typical buyer is willing to pay for full or partial control of Aprea Therapeutics. Since Aprea Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aprea Stock. However, Aprea Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.73 | Real 2.21 | Target 6.67 | Hype 0.74 | Naive 0.65 |
The real value of Aprea Stock, also known as its intrinsic value, is the underlying worth of Aprea Therapeutics Company, which is reflected in its stock price. It is based on Aprea Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Aprea Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Aprea Therapeutics helps investors to forecast how Aprea stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aprea Therapeutics more accurately as focusing exclusively on Aprea Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Aprea Therapeutics' intrinsic value based on its ongoing forecasts of Aprea Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Aprea Therapeutics' closest peers. If more than one evaluation category is relevant for Aprea Therapeutics we suggest using both methods to arrive at a better estimate.
Aprea Therapeutics Cash |
|
Aprea Therapeutics Total Value Analysis
Aprea Therapeutics is presently projected to have valuation of (9.59 M) with market capitalization of 5.57 M, debt of 4.67 M, and cash on hands of 39.06 M. The negative valuation of Aprea Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Aprea Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(9.59 M) | 5.57 M | 4.67 M | 39.06 M |
Aprea Therapeutics Investor Information
About 20.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.51. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aprea Therapeutics recorded a loss per share of 2.12. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 13th of February 2023. Based on the key indicators related to Aprea Therapeutics' liquidity, profitability, solvency, and operating efficiency, Aprea Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Aprea Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aprea Therapeutics has an asset utilization ratio of 6.27 percent. This indicates that the Company is making $0.0627 for each dollar of assets. An increasing asset utilization means that Aprea Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Aprea Therapeutics Profitability Analysis
Based on Aprea Therapeutics' profitability indicators, Aprea Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Aprea Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2013-09-30 | Previous Quarter -3.2 M | Current Value -3 M | Quarterly Volatility 16.7 M |
For Aprea Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aprea Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aprea Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aprea Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aprea Therapeutics over time as well as its relative position and ranking within its peers.
Aprea Therapeutics Earnings per Share Projection vs Actual
By analyzing Aprea Therapeutics' earnings estimates, investors can diagnose different trends across Aprea Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Aprea Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Aprea Therapeutics Ownership Allocation
Aprea Therapeutics shows significant amount of outstanding shares owned by insiders and institutional investors .Aprea Therapeutics Profitability Analysis
The company reported the previous year's revenue of 1.5 M. Net Loss for the year was (12.96 M) with loss before overhead, payroll, taxes, and interest of (7.91 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Aprea Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Aprea Therapeutics and how it compares across the competition.
About Aprea Therapeutics Valuation
The stock valuation mechanism determines Aprea Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Aprea Therapeutics. We calculate exposure to Aprea Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aprea Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -7.1 M | -6.7 M | |
| Pretax Profit Margin | (7.76) | (8.15) | |
| Operating Profit Margin | (8.58) | (9.01) | |
| Net Loss | (7.76) | (8.15) | |
| Gross Profit Margin | (6.02) | (5.72) |
Aprea Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Aprea Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Aprea we look at many different elements of the entity such as Aprea's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Aprea Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Aprea Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Aprea Therapeutics' worth.Complementary Tools for Aprea Stock analysis
When running Aprea Therapeutics' price analysis, check to measure Aprea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aprea Therapeutics is operating at the current time. Most of Aprea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aprea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aprea Therapeutics' price. Additionally, you may evaluate how the addition of Aprea Therapeutics to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |